Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
11/01/23 4:05 PM EDT
ELEVIDYS net product revenues for the quarter totaled $69.1 million
Total revenues, which consist of net product revenues and collaboration revenues, for the third quarter 2023 totaled $331.8 million
Net product revenues for the third quarter 2023 totaled $309.3 million, a 49% increase over the same quarter of prior year
From Sarepta announcement.
Sarepta gene therapy study missed key target in Duchennes, page-414
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.6¢ | 7.5¢ | $13.48K | 179.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 414315 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 151776 | 1 |
View Market Depth
| Last trade - 12.35pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.5¢ |
Change
0.000 ( 3.60 %) |
||||
| Open | High | Low | Volume | ||
| 7.5¢ | 7.5¢ | 7.5¢ | 50815 | ||
| Last updated 12.35pm 22/05/2024 ? | |||||
| PER (ASX) Chart |